CAJ | 학술논문

目的观察止嗽散加味颗粒剂联合信必可治疗咳嗽变异性哮喘的疗效.方法 120 例咳嗽变异性哮喘患者,采用完全随机分组法分为两组各60 例.对照组采用信必可布地奈德福莫特罗粉吸入剂吸入治疗,治疗组在对照组治疗基础上联用止嗽散加味颗粒剂治疗.结果治疗显效率为83.3%,优于对照组的70.0%(P＜0.05).两组患者经治疗后,咳嗽、咽痒、气急、咯痰均明显好转,且治疗组优于对照组(χ2 值分别为7.46、7.86、8.41,9.35,P 均＜0.05).肺功能第1 秒用力呼气容积(forced expiratory volume in one second,FEV1)、FEV1%和呼气峰流速(PEF )均有改善,治疗组治疗前后比较差异有统计学意义(t＝2.351,P＜0.05);治疗后组间比较差异有统计学意义(t＝2.452,P＜0.05);两组治疗后外周血EOS、ECP、IL-5 均降低(t＝4.952,P＜0.01),治疗组对ECP 和IL-5 的改善优于对照组(t＝3.936,P＜0.01).结论止嗽散加味颗粒剂联合信必可治疗咳嗽变异性哮喘有效.
목적 관찰지수산가미과립제연합신필가치료해수변이성효천적료효.방법 120 례해수변이성효천환자,채용완전수궤분조법분위량조각60 례.대조조채용신필가포지내덕복막특라분흡입제흡입치료,치료조재대조조치료기출상련용지수산가미과립제치료.결과 치료현효솔위83.3%,우우대조조적70.0%(P＜0.05).량조환자경치료후,해수、인양、기급、각담균명현호전,차치료조우우대조조(χ2 치분별위7.46、7.86、8.41,9.35,P 균＜0.05).폐공능제1 초용력호기용적(forced expiratory volume in one second,FEV1)、FEV1%화호기봉류속(PEF )균유개선,치료조치료전후비교차이유통계학의의(t＝2.351,P＜0.05);치료후조간비교차이유통계학의의(t＝2.452,P＜0.05);량조치료후외주혈EOS、ECP、IL-5 균강저(t＝4.952,P＜0.01),치료조대ECP 화IL-5 적개선우우대조조(t＝3.936,P＜0.01).결론 지수산가미과립제연합신필가치료해수변이성효천유효.
Objective To observe the clinical effect of modified Zhisou powder and Symbicort Turbuhaler simultaneously on patients with Cough Variant Asthma. Methods 120 patients with Cough Variant Asthma were randomly recurited into two groups. 60 patients in the treatment group were treated with modified Zhisou powder and Symbicort Turbuhaler; 60 patients in the control group were treated with Symbicort Turbuhaler. 4 weeks was a therapeutic course in both group. Results The markedly controlled rate (MCR) (clinical control+excenence)of the treatment group was 83.3%, obviously surpassed the control group (70.0%) (P＜0.05); There was obvious improvement of cough, expectoration, breath lessness and throaty pruritus after the therapy in both groups, but it was much better in the treatment group than the control group(P＜0.05). The pulmonary function was significantly improved after treatment in both groups(FEV1, FEV1% and PEF, P＜0.05). The improvement showed significant difference between the two groups(P＜0.05). There was obvious decrease of EOS, IL-5 and ECP in both groups. The decrease of ECP and IL-5 in the treatment group was greater than the control group(P＜0.01). Conclusion The therapy of modified Zhisou powder and Symbicort Turbuhaler has advantage over pure western therapy.